Catasys (CATS) Upgraded to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of Catasys (NASDAQ:CATS) from a sell rating to a hold rating in a report published on Thursday.
According to Zacks, “Catasys, Inc., formerly known as Hythiam, Inc., provides specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Company’s program seeks to improve member health by delivering medical and psychosocial interventions in combination with long term care coaching, including their proprietary treatment program for alcoholism and stimulant dependence. Catasys, Inc. is based in Los Angeles. “
Several other equities analysts have also commented on the company. ValuEngine lowered Catasys from a hold rating to a sell rating in a research report on Saturday, October 21st. Taglich Brothers assumed coverage on Catasys in a research report on Wednesday, October 18th. They set a speculative buy rating and a $8.00 price objective for the company. Finally, Telsey Advisory Group assumed coverage on Catasys in a research report on Wednesday, October 18th. They set a buy rating for the company.
Catasys (NASDAQ:CATS) last announced its quarterly earnings results on Tuesday, November 14th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.04). analysts predict that Catasys will post -0.89 earnings per share for the current fiscal year.
Catasys Company Profile
Catasys, Inc provides data analytics based specialized behavioral health management and integrated treatment services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services. The companys OnTrak solution includes medical and psychosocial interventions; and a proprietary Web based clinical information platform and database, psychosocial programs, and integrated care coaching services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catasys and related companies with MarketBeat.com's FREE daily email newsletter.